Zirconium Zr 89-DFO-REGN3504
Zirconium Zr 89-DFO-REGN3504 - A radioimmunoconjugate consisting of an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 PD-L1; cluster of differentiation 274; CD274, linked, via the chelator desferrioxamine DFO, to the radioisotope zirconium Zr 89 Zr89, with potential diagnostic properties upon positron emission tomography PET imaging. Upon administration, the antibody moiety of zirconium Zr 89-DFO-REGN3504 specifically targets and binds to PD-L1. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Admin, Prab R. Tumpati, MD